Julie L Boyer

US Patent:

7863425, Jan 4, 2011

Filed:

Sep 25, 2008

Appl. No.:

12/238129

Inventors:

Ronald G Crystal - New York NY, US
Julie L Boyer - New York NY, US

Assignee:

Cornell University - Ithaca NY

International Classification:

C07K 16/00

US Classification:

5303881, 435340

Abstract:

The invention provides a gene transfer vector for inducing an immune response against in a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins of and/or a nucleic acid sequence encoding a monoclonal antibody directed against. The invention further provides a method of producing an immune response against in a mammal comprising administration of the gene transfer vector to the mammal. The invention also provides a monoclonal antibody directed against the Virulence (V) antigen of , as well as a hybridoma cell line producing same and a nucleic acid sequence encoding same.

US Patent:

20110086063, Apr 14, 2011

Filed:

Jun 4, 2009

Appl. No.:

12/995851

Inventors:

Ronald G. Crystal - New York NY, US
Philip L. Leopold - Basking Ridge NJ, US
Stefan Worgall - New York NY, US
Julie L. Boyer - New York NY, US

Assignee:

CORNELL UNIVERSITY - Ithaca NY

International Classification:

A61K 39/235
A61K 31/7088
A61P 25/36
A61P 25/30
A61P 25/34
C12N 7/00
C12N 15/63

US Classification:

4241991, 4242331, 514 44 R, 4352351, 4353201

Abstract:

The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector.

US Patent:

20130090375, Apr 11, 2013

Filed:

Jun 29, 2012

Appl. No.:

13/537457

Inventors:

Ronald G. Crystal - New York NY, US
Stephen M. Kaminsky - Bronx NY, US
Donald Joseph D'Amico - New York NY, US
Julie Boyer - Guilford CT, US
Szilard Kiss - New York NY, US

Assignee:

CORNELL UNIVERSITY - Ithaca NY

International Classification:

A61K 31/7088
A61P 9/00
A61P 27/02

US Classification:

514 44 R

Abstract:

The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.

US Patent:

7022496, Apr 4, 2006

Filed:

Jul 13, 2001

Appl. No.:

09/904698

Inventors:

Gary Ketner - Columbia MD, US
Julie L. Boyer - New York NY, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12P 21/00

US Classification:

435 691, 4241841, 4242331, 4242041, 4242771, 4242781, 530300, 530350, 530 2372

Abstract:

The present invention provides a modified adenovirus comprising genomic adenoviral DNA which has been modified so that (i) the only gene product of the early region (E4) that is expressed is open reading frame 6 (ORF-6), (ii) neither the gene product of the E1A region nor the gene product of the E1B region is expressed, and (iii) no other early or late gene products are expressed. The present invention also provides methods of inhibiting repair of breaks in double-stranded DNA in a cell, preventing concatamerization of linear wild-type adenoviral DNA, inhibiting V(D)J recombination of nucleic acid sequences encoding immunoglobulins, preventing apoptosis, and preventing and treating cancer.

US Patent:

20180291154, Oct 11, 2018

Filed:

Jun 15, 2018

Appl. No.:

16/009366

Inventors:

- WATERFORD NY, US
Julie L. Boyer - Columbia MD, US

International Classification:

C08G 77/08
C09D 143/04
C07F 7/18
C07F 7/14
C07F 7/08
C09D 183/04
C08G 77/00
C07F 7/12

Abstract:

A process and composition for the hydrosilylation of an unsaturated compound comprising reacting (a) a silyl hydride with (b) an unsaturated compound in the presence of (c) a platinum compound and (d) a cyclodiene, with the proviso that when the unsaturated compound is a terminal alkyne, the silyl hydride is other than a halosilane. The process and composition optionally comprise an inhibitor (e). The process and composition may be employed to form a variety of hydrosilylation products.

US Patent:

20180015449, Jan 18, 2018

Filed:

Sep 26, 2017

Appl. No.:

15/715324

Inventors:

- Waterford NY, US
- Princeton NY, US
Julie Boyer - Columbia MD, US
Paul Chirik - Princeton NJ, US
Johannes G.P. Delis - Bergen op Zoom, NL
Kenrick Lewis - Flushing NY, US
Susan A. Nye - Feura Bush NY, US

International Classification:

B01J 31/18

Abstract:

Disclosed herein is the use of manganese, iron, cobalt, or nickel complexes containing tridentate pyridine di-imine ligands as hydrosilylation catalysts. These complexes are effective for efficiently catalyzing hydrosilylation reactions, as well as offering improved selectivity and yield over existing catalyst systems.

US Patent:

20150182638, Jul 2, 2015

Filed:

Mar 12, 2015

Appl. No.:

14/645630

Inventors:

- Ithaca NY, US
Stephen M. Kaminsky - Bronx NY, US
Donald Joseph D'Amico - New York NY, US
Julie Boyer - Guilford CT, US
Szilard Kiss - New York NY, US

International Classification:

A61K 48/00
C12N 15/86
A61K 9/00
C07K 16/22

Abstract:

The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.

US Patent:

20140330036, Nov 6, 2014

Filed:

Apr 2, 2014

Appl. No.:

14/243044

Inventors:

Kenrick Martin Lewis - Flushing NY, US
Crisita Carmen Hojilla Atienza - Houston TX, US
Julie L. Boyer - Watervliet NY, US
Paul J. Chirik - Princeton NJ, US
Johannes G.P. Delis - Bergen op Zoom, NL
Aroop Kumar Roy - Mechanicville NY, US

Assignee:

PRINCETON UNIVERSITY - Princeton NJ
MOMENTIVE PERFORMANCE MATERIALS INC. - Waterford NY

International Classification:

C07F 7/08

US Classification:

556481

Abstract:

The present invention relates to processes for the synthesis of saturated and unsaturated silahydrocarbons using iron-containing or cobalt-containing catalysts. The processes of the invention can produce tetraalkylsilanes, phenyltrialkylsilanes, substituted phenyltrialkylsilanes and their mixtures, which are useful as lubricants and hydraulic fluids, as well as alkyl alkenylsilanes, phenyl alkenylsilanes and substituted phenyl alkenylsilanes and their mixtures, which are useful in the synthesis of saturated silahydrocarbons and other organofunctional silanes.